XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Significant Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 08, 2021
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Purchases to acquire equity securities         $ 4.6 $ 0.0
Revenues   $ 296.0   $ 258.5 821.5 798.0
Collaborative Arrangement | Takeda            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments   1,900.0     1,900.0  
Collaborative Arrangement | Idorsia            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments   1,700.0     1,700.0  
Collaborative Arrangement | Xenon            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments   1,700.0     1,700.0  
Milestone payment $ 10.0          
Research and development $ 4.5          
Number of shares owned (in shares) 300          
Common stock per share (in USD per share) $ 19.9755          
Milestone purchase payment $ 5.5          
Purchases to acquire equity securities 4.6          
Premium paid for equity purchase $ 0.9          
Collaborative Arrangement | Voyager            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments   1,300.0     1,300.0  
Collaborative Arrangement | BIAL            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments   75.0     75.0  
Collaborative Arrangement | MTPC            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Deferred revenue recognized   0.9   0.5 3.3 1.8
Collaborative Arrangement | License | MTPC            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payment receipts   55.0     55.0  
Revenues     $ 15.0      
Deferred revenue, balance   3.5     3.5  
Collaborative Arrangement | Royalty | AbbVie            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payment receipts   366.0     366.0  
Revenues   $ 5.9   $ 3.9 $ 16.3 $ 13.4